Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab + Stereotactic Radiosurgery in Melanoma Brain Metastases
NCT02662725Phase 2Completed
- Sponsor
- CHU de Lille
- Start
- Sep 2012
- Primary completion
- Dec 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ipilimumab in melanoma, sponsored by CHU de Lille. Primary endpoint: Overall survival rate at 96 weeks. Started Sep 2012; status: completed.
02
Drugs
ipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02662725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02662725.